Table 2.
Incremental cost effectiveness ratio by quality adjusted life year
| Treatment | Cost of medications for seven cycles | Mean total costs for seven cycles (US$) | ICER | Reference |
|---|---|---|---|---|
| CP | $571 | $32,966 | – | 12,17 |
| CP+B | $61,671 | $96,842 | $133,559/QALY | 12,17 |
| PT | $9,211 | $71,620 | $511,947/QALY | 12,17 |
| PT+B | $70,312 | $109,211 | $124,576/QALY | 12,17 |
Abbreviations: CP, cisplatin/paclitaxel; CP+B, cisplatin/paclitaxel/bevacizumab; PT, paclitaxel/topotecan; PT+B, paclitaxel/topotecan/bevacizumab; ICER, incremental cost-effectiveness ratio; QALY, quality adjusted life year.